ClinicalTrials.gov
North Carolina, United States · <25 Employees
View Company Info for Free
About
Headquarters
200 Morris St, Durham, North Carolina, 27701, U...Phone Number
(919) 668-3437Website
www.clinicaltrials.govRevenue
$10.2 MillionIndustry
Who is ClinicalTrials.gov
ClinicalTrials.gov Org Chart
Is ClinicalTrials.gov your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ClinicalTrials.gov is spiking on competitors!
Check if ClinicalTrials.gov has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ClinicalTrials.gov
Funding: Get notified immidiatlly once ClinicalTrials.gov has new funding data
Earning: See what the market has to say on ClinicalTrials.gov recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ClinicalTrials.gov launches new products
ClinicalTrials.gov, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ClinicalTrials.gov had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ClinicalTrials.gov
Find 2 more new buyers
Compare Similar Companies to ClinicalTrials.gov
Compare insights from companies similar to ClinicalTrials.gov, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ClinicalTrials.gov
ClinicalTrials.gov Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
ClinicalTrials.gov Tech Stack
A closer look at the technologies used by ClinicalTrials.gov
ClinicalTrials.gov News & Media
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today announced the dosing of the first participant in its ANDECAL study, a Phase 2/3 clinical trial evaluating the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP). The dosing milestone for andecaliximab, āsClinical Trials Market Size to Reach $73.33 Billion By 2031 | CAGR 6.8%: The Insight Partners
Clinical Trials Market Experiences Growth Due to Preference for Outsourcing Manufacturing Operations, full analysis by Product, Application, Source, Manufacturing, and Geography NEW YORK, Oct. 28, 2024 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the...The Texas Heart Institute Implants BiVACOR® Total Artificial Heart
HOUSTON--(BUSINESS WIRE)--The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR’s TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces bothLiveSpo represents Vietnam to announce the world's first spore probiotics in nasal spray form at the BIO International Convention
BOSTON, June 6, 2023 /PRNewswire/ -- LiveSpo is the first representative from Vietnam to participate in the BIO International Convention, an exhibition showcasing breakthrough biotechnology solutions, held in Boston, USA. This demonstrates the remarkable development of the Vietnamese pharmaceutical field in the realm of biotechnology. LiveSpo represents Vietnam to announce the world's first spore probiotics in nasal spray form at the BIO International Convention Dr. Nguyen Hoa Anh - R&D DirectorK36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director
KTX-1001 is the first inhibitor of multiple myeloma SET domain (MMSET) to enter clinical development MMSET is the oncogenic driver of multiple myeloma in patients with genetic translocation t(4;14), reported to be undruggable CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- K36...
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding ClinicalTrials.gov
ClinicalTrials.gov provides patients, families and members of the public easy access to information about the location of clinical trials, their design and purpose, criteria for participation, and, in many cases, further information about the disease and treatment under study. There are also contact points for individuals responsible for recruiting... Read More